Novartis’s net profit for 9 months has fallen by more than a quarter


Net profit of pharmaceutical company Novartis for the first 9 months of 2015 amounted to 5,974 billion, a decrease of 28%, in recalculation on one share – 2,48 3,37 dollar against the dollar a year earlier.

MOSCOW, 27 Jan. Net profit of pharmaceutical company Novartis for the first 9 months of 2015 amounted to 5,974 billion, a decrease of 28% in annual terms, stated in the financial statements of a pharmaceutical company.

The net profit in recalculation on one share amounted at the end of the reporting period 2,48 3,37 dollar against the dollar a year earlier. Novartis sales for the first 9 months of this year amounted to $ 36,894 billion, a decrease compared to last year’s figure by 6%.

In the third quarter of 2015 the company’s net profit amounted to 1,812 billion, which is 42% lower than the same period of 2014. Earnings per share amounted to $ 0.75 per dollar of 1.27 against the dollar a year earlier. The company’s sales also declined as it amounted in the reporting quarter 12,265 billion, which is 6% lower than a year ago.

“Novartis has continued to make great progress in innovation in the third quarter,” said CEO of Novartis Joseph Jimenez (Jimenez Joseph).

Novartis International AG, was founded in 1996 in Basel, Switzerland, ranked second in market share in the pharmaceutical market of Europe. The company operates in 140 countries, including in Russia.